Imbria secures $57.5m to advance ninerafaxstat through Phase IIb nHCM trial

The therapy has demonstrated encouraging outcomes in Phase IIa trials for nHCM and heart failure with preserved ejection fraction. Credit: jesse orrico on Unsplash.